COMBINATION THERAPY WITH TARGETED 4-1BB (CD137) AGONISTS

The present application relates to combination therapies employing tumor targeted anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists, in particular 4-1BBL trimer containing antigen binding molecules, the use of these combination therapies for the treatment of cancer and methods of using the c...

Full description

Saved in:
Bibliographic Details
Main Authors BACAC MARINA, FERRARA KOLLER CLAUDIA, LANG SABINE, LEVITSKI VIKTOR, KLEIN CHRISTIAN, UMANA PABLO, CLAUS CHRISTINA
Format Patent
LanguageChinese
English
Published 02.08.2019
Subjects
CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

Abstract The present application relates to combination therapies employing tumor targeted anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists, in particular 4-1BBL trimer containing antigen binding molecules, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies. The trimer CEA-4-1BBL (Figure IB) provides the highest tumor regression when combined with CEA CD3 TCB (See table 18). 本申请涉及采用肿瘤靶向性抗CD3双特异性抗体和4-1BB(CD137)激动剂,特别是含有4-1BBL三聚体的抗原结合分子的组合疗法,这些组合疗法用于治疗癌症的用途和使用该组合疗法的方法。三聚体CEA-4-1BBL(图1B)在与CEA CD3 TCB组合时提供最高肿瘤消退(见表18)。
AbstractList The present application relates to combination therapies employing tumor targeted anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists, in particular 4-1BBL trimer containing antigen binding molecules, the use of these combination therapies for the treatment of cancer and methods of using the combination therapies. The trimer CEA-4-1BBL (Figure IB) provides the highest tumor regression when combined with CEA CD3 TCB (See table 18). 本申请涉及采用肿瘤靶向性抗CD3双特异性抗体和4-1BB(CD137)激动剂,特别是含有4-1BBL三聚体的抗原结合分子的组合疗法,这些组合疗法用于治疗癌症的用途和使用该组合疗法的方法。三聚体CEA-4-1BBL(图1B)在与CEA CD3 TCB组合时提供最高肿瘤消退(见表18)。
Author LEVITSKI VIKTOR
BACAC MARINA
CLAUS CHRISTINA
UMANA PABLO
LANG SABINE
FERRARA KOLLER CLAUDIA
KLEIN CHRISTIAN
Author_xml – fullname: BACAC MARINA
– fullname: FERRARA KOLLER CLAUDIA
– fullname: LANG SABINE
– fullname: LEVITSKI VIKTOR
– fullname: KLEIN CHRISTIAN
– fullname: UMANA PABLO
– fullname: CLAUS CHRISTINA
BookMark eNrjYmDJy89L5WSwcPb3dfL0cwzx9PdTCPFwDXIMiFQI9wzxUAhxDHJ3DXF1UTDRNXRyUtBwdjE0NtdUcHT39_MMDgnmYWBNS8wpTuWF0twMim6uIc4euqkF-fGpxQWJyal5qSXxzn6GhgYGFuZmFkaOxsSoAQAZXyls
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
DocumentTitleAlternate 用靶向性4-1BB(CD137)激动剂的组合疗法
ExternalDocumentID CN110087682A
GroupedDBID EVB
ID FETCH-epo_espacenet_CN110087682A3
IEDL.DBID EVB
IngestDate Fri Jul 19 12:50:24 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language Chinese
English
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_CN110087682A3
Notes Application Number: CN201780078076
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20190802&DB=EPODOC&CC=CN&NR=110087682A
ParticipantIDs epo_espacenet_CN110087682A
PublicationCentury 2000
PublicationDate 20190802
PublicationDateYYYYMMDD 2019-08-02
PublicationDate_xml – month: 08
  year: 2019
  text: 20190802
  day: 02
PublicationDecade 2010
PublicationYear 2019
RelatedCompanies HOFFMANN LA ROCHE
RelatedCompanies_xml – name: HOFFMANN LA ROCHE
Score 3.342507
Snippet The present application relates to combination therapies employing tumor targeted anti-CD3 bispecific antibodies and 4-1BB (CD137) agonists, in particular...
SourceID epo
SourceType Open Access Repository
SubjectTerms CHEMISTRY
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PEPTIDES
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Title COMBINATION THERAPY WITH TARGETED 4-1BB (CD137) AGONISTS
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20190802&DB=EPODOC&locale=&CC=CN&NR=110087682A
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LS8NAEB5qFfWmVdH6YAUJegg27_QQJNkkTYQmpY3ankp3k6Ie2mIjgr_eSUytF70tuzDMDnwzs7sz3wJctZmMeSfPxDbjTFS5qYoMASkqupJi_mDqTC8anLuRHjyo90NtWIPXVS9MyRP6UZIjIqI44j0v_fVifYnllrWVy1v2glPzOz-xXKE6HWN0M1uy4DqW14vdmAqUWjQSor5VMKMh8E3Z3oDNIo0uePa9R6foSln8Din-Hmz1UNos34fa53MDdujq57UGbHerB28cVthbHoBJ464TfrPXkiTw-nZvRJ7CJCCJ3e946IGIKkqOQ66pKynGDbE7cRQOksEhXPpeQgMRVRj_7HdMo7W2yhHUZ_NZdgzERLekS1MtY2mmMmZMFEnVpqkmc8ZbE0M6gebfcpr_LZ7CbmG7sq5NPoN6_vaenWOszdlFaaQvAk18qw
link.rule.ids 230,309,786,891,25594,76906
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1LT8JAEJ4gGvGmqFF8rYlp9NBI3-XQmHZbaJW2BFbFE2FLiXoAIjUm_nqnFcSL3ja7yWR2km9mdnfmW4CLBpcx70xSscETLqqJqYocASkqujLC_MHUuZ43OIeR7t-rt32tX4LXZS9MwRP6UZAjIqISxHtW-OvZ6hLLLWor59f8BaemN01mucLidIzRzazLgutYXid2YypQatFIiLpWzoyGwDdlew3WjZydN0-dHpy8K2X2O6Q0t2Gjg9Im2Q6UPp-rUKHLn9eqsBkuHrxxuMDefBdMGodO8M1eS5jvde3OE3kMmE-Y3W156IGIKkqOQy6pKynGFbFbcRT0WG8Pzpseo76IKgx-9jug0UpbZR_Kk-kkPQBiolvSpbGW8lGqcm4MFUnVxiNNTnhSHxrSIdT-llP7b_EMKj4L24N2EN0dwVZux6LGTT6Gcvb2np5g3M34aWGwL_7Yf5g
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=COMBINATION+THERAPY+WITH+TARGETED+4-1BB+%28CD137%29+AGONISTS&rft.inventor=BACAC+MARINA&rft.inventor=FERRARA+KOLLER+CLAUDIA&rft.inventor=LANG+SABINE&rft.inventor=LEVITSKI+VIKTOR&rft.inventor=KLEIN+CHRISTIAN&rft.inventor=UMANA+PABLO&rft.inventor=CLAUS+CHRISTINA&rft.date=2019-08-02&rft.externalDBID=A&rft.externalDocID=CN110087682A